sTREM2 has been used as a microglial activation marker, and its levels were found to be high in the cerebrospinal fluid (CSF) of patients with AD; moreover, it correlates positively with total and phosphorylated tau levels [30, 31, 32]. Here, MAPT is linked to Alzheimer disease.